Study withdrawn: extended access to fostamatinib for transplant patients never launched

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: * Subjects who were enrolled on phase II trial of fostamatinib and deemed responders at the time of rollover to the extended access trial which is defined as: * Hemoglobin \>= 9 g/dL (or at least \>= 1 g/dL above baseline) in subjects enrolled with posttransplant anemia without transfusion support, at least once during the 12-week phase II trial. OR --Platelets \>= 30 X 10\^9/L (or at least \>= 10 X 10\^9/L above baseline) without transfusion support, at least once during the 12-week phase II trial, in subjects enrolled with posttransplant thrombocytopenia OR --Either of the above criteria in subjects with posttransplant Evans syndrome * Completed the end of study visit (week 12) on the initial protocol (A Phase II Study of Syk-inhibition using Fostamatinib to treat Post-Transplant Immune-mediated Cytopenias). * Female patients of reproductive potential agree to avoid pregnancy through abstinence or the use two forms of highly effective birth control during and for 1 month after the last study treatment and agree not to donate eggs during this time. * Male patients of reproductive potential agree to avoid pregnancy of a partner through abstinence or the use two forms of highly effective birth control during and for 1 month after the last study treatment and agree not to donate sperm during this time. EXCLUSION CRITERIA: * Severe psychiatric illness or mental deficiency sufficient to make making informed consent impossible * Positive pregnancy test for women of childbearing age within 1 week or being actively lactating * Uncontrolled hypertension (systolic blood pressure \>140mmHg or diastolic blood pressure \>90mmHg) * ALT or AST \>3 times the upper limit of normal * Patients who have a history of medical disorders, that in the investigator's opinion, could affect the conduct of the study or the absorption, metabolism or excretion of the study drug are excluded. * Patients with evidence of graft rejection (based on clinical suspicion supported by BM biopsy data and/or chimerism studies and/or MLR) * Neutropenia, defined as absolute neutrophil count \<= 1.0 X 10\^9/L * Non-immune mediated cytopenias. Etiologies including, but not limited to, cytopenias due to HIV infection, lymphoproliferative disorders, myelodysplasia/acute leukemia, drug-induced thrombocytopenia, thrombotic microangiopathies, acute bleeding, consumptive coagulopathy, fever, infections leading to cytopenia, medications induced cytopenias, thrombotic microangiopathies (disseminated intravascular coagulation), splenomegaly or hemophagocytic lymphohistiophagocytosis, relapse of primary disease.